34 results about "Kidney inflammation" patented technology

The invention belongs to the technical field of microorganisms, and relates to a lactobacillus paracasei JNL0025 strain and application thereof. Compared with a commercial strain lactobacillus casei substitute strain, the lactobacillus paracasei JNL0025 provided by the invention has the advantages that the guanine nucleoside conversion rate is improved, the inhibition rate of supernate on XOD is equivalent, and the inhibition on PNP activity can be realized; according to the lactobacillus paracasei JNL0025 disclosed by the invention, the lactobacillus paracasei JNL0025 has the effects of reducing the tendency of pro-inflammatory M1 type macrophages, increasing the proportion of anti-inflammatory M2 type macrophages and inhibiting secretion of pro-inflammatory cytokines TNF-alpha and IL-6, and the lactobacillus paracasei JNL0025 has a better inflammation inhibition effect than the lactobacillus rhamnosus LGG; animal experiment results show that the lactobacillus paracasei JNL0025 provided by the invention can significantly reduce the blood uric acid level of a hyperuricemia model mouse, alleviate the kidney inflammation level and alleviate DSS-induced colitis, and shows a huge application value.

The preservation number of the bacterial strain is CGMCC (China General Microbiological Culture Collection Center) NO.33629, the preservation date of the bacterial strain is February 24, 2025, the preservation classification of the bacterial strain is Lactobacillus sakei, and the preservation unit of the bacterial strain is China General Microbiological Culture Collection Center. The strain provided by the invention can reduce the concentration of blood uric acid, relieve kidney inflammation caused by hyperuricemia, improve the protein level of a kidney uric acid excretion channel and reduce the expression level of uric acid resorption protein.

By constructing a mouse model of the specific knockout TILRR, it is found that the specific knockout TILRR remarkably slows down the kidney inflammation signal flow of an object, inhibits kidney diseases of the object and reduces the kidney fibrosis degree and / or inflammatory response of the object. Thus, the present invention relates to the use of TILRR as a target in the prevention and / or treatment of kidney disease. Specifically, the invention provides application of the following reagents in preparation of drugs for slowing down kidney inflammation signal flow of an object, inhibiting kidney diseases of the object and reducing kidney fibrosis degree and / or inflammatory response of the object: (1) a reagent for reducing expression of TILRR protein of the object; and / or (2) an agent that reduces the activity of a TILRR protein expressed by a subject.

The invention relates to a human recombinant GDF15 protein and application thereof in preparation of drugs for preventing and treating sepsis acute kidney injury, and belongs to the technical field of biological medicines. In order to solve the problem that an effective prevention and treatment scheme for improving SA-AKI by inhibiting oxygen death is lacked in existing clinical and research, the invention provides a human recombinant GDF15 protein of which the coding gene nucleotide sequence is shown as SEQ ID No: 1. Animal experiment results show that by intraperitoneal injection of the human recombinant GDF15 protein, kidney inflammation of sepsis mice can be relieved, and expression of PGAM5 can be down-regulated. Cell experiment results show that when the human recombinant GDF15 protein is given, LPS-induced USF2 increase can be inhibited. The human recombinant GDF15 protein provided by the invention can improve SA-AKI by inhibiting oxygen death and inflammation, provides a new idea and an intervention target for prevention and treatment of SA-AKI, and shows a good clinical application prospect.

The invention discloses a preparation method and application of hydrolyzed casein peptide capable of reducing uric acid and facilitating gout attack prevention and gout symptom improvement, belongs to the technical field of biology, and has a wide application prospect. The casein hydrolysate peptide prepared by the method disclosed by the invention can effectively reduce uric acid, and is beneficial to preventing gout attack and improving gout symptoms by the following ways: 1, inhibiting the activity of xanthine oxidase (UA enzyme), and reducing the generation of uric acid; 2, metal ions such as Ca < 2 + > and Na < + > are complexed to prevent generation of urate crystals, so that gout attack can be prevented; 3, the microenvironment of an articular cavity is improved, urate crystals are dissolved, and the gout symptom can be improved; and 4, liver and kidney inflammation caused by high uric acid is relieved.

The invention belongs to the technical field of biological medicine, and particularly relates to application of macrophage LSR gene and / or LSR protein in preparation of drugs and diagnostic products for preventing and / or treating diabetic nephropathy. Research finds that the LSR deletion of macrophages aggravates renal injury by promoting inflammatory response of diabetic nephropathy and increasing lipid renal toxicity; on the contrary, after the LSR expression of the macrophages is recovered, the inflammatory response and lipid droplet deposition of the kidney of the diabetic nephropathy mouse can be effectively reduced, and meanwhile, the kidney injury is improved. Cell experiments show that LSR deletion of macrophages can activate a YAP signal channel to increase secretion of inflammatory factors and reduce low-density lipoprotein uptake at the same time. Therefore, the macrophage LSR can be used as a diabetic nephropathy drug target, a gene therapy target gene and an auxiliary diagnosis marker, and a new theoretical basis and an intervention strategy are provided for prevention and treatment of the disease.

According to various aspects of this disclosure, the present disclosure relates to methods for reducing kidney inflammation, reducing kidney fibrosis, reducing oxidative stress in the kidney, preventing or reducing the likelihood of chronic kidney disease (CKD), treating or preventing acute kidney injury (AKI) or treating a kidney disease in a subject in need thereof comprising administering, e.g., intramuscularly, to the subject a recombinant adeno-associated virus (rAAV) vector, wherein the rAAV vector comprises a vector genome comprising a nucleotide sequence encoding a Fibroblast growth factor 21 (FGF21) or a functional fragment thereof and an AAV capsid (e.g., AAV1 serotype), optionally, wherein the subject does not suffer from diabetes.

The invention discloses raspberry leaf polysaccharide as well as a preparation method and application thereof. The average relative molecular weight of the raspberry leaf polysaccharide is 44755 Da, and the raspberry leaf polysaccharide is mainly prepared from mannose, glucose, rhamnose, glucosamine, galactosamine, glucuronic acid, galactose, xylose and arabinose according to the molar ratio of (3.138): (0.894): (12.349): (4.590): (26.498): (18.681): (22.842): (2.690): (8.317). Besides, methylation and nuclear magnetic resonance analysis show that the raspberry leaf polysaccharide is complex polysaccharide, and it can be reasonably deduced that the raspberry leaf polysaccharide is mainly composed of a large number of HG structural domain-like structures and a part of RG-I structures with side chains. Meanwhile, the raspberry leaf polysaccharide disclosed by the invention can be used for inhibiting the injury of kidney tissues and reducing the generation of kidney inflammatory factors.

The invention provides a composition with the effects of reducing uric acid and improving the renal function and a preparation method, application and a product of the composition, and belongs to the field of traditional Chinese medicine application. The composition is prepared from the following components: raw radix astragali, rhizoma smilacis glabrae, herba taxilli, radix salviae miltiorrhizae and rhizoma alismatis. According to the composition provided by the invention, the raw radix astragali, the rhizoma smilacis glabrae, the herba taxilli, the radix salviae miltiorrhizae and the rhizoma alismatis are combined for use, and the obtained composition can be used for treating hyperuricemia or related diseases thereof, and is remarkable in curative effect and small in toxic and side effects. The composition is used for post-treatment of hyperuricemia and is used for treating arthralgia and pain of joints and unfavorable flexion and extension. Meanwhile, the composition has a certain kidney protection effect and can reduce kidney inflammation and fibrosis.

The invention discloses an ICAM-1 targeting engineered exosome-metal phenol nano-drug as well as a preparation method and application thereof. The nano-drug is composed of an engineered exosome and metal phenol nano-particles, wherein ICAM-1 targeting VHH antibodies are displayed on the surface of the engineered exosome, and the metal phenol nano-particles are encapsulated in the engineered exosome and formed by self-assembly of iron ions and resveratrol. The MPNs are efficiently loaded into the exosome through an electroporation method, and a composite nano delivery system (ICAM (at) Exo (at) MPNs) is constructed. The system has multiple advantages of active targeting of kidney inflammation parts, active oxygen responsive drug release, simulation of antioxidant enzyme activity, regulation and control of macrophage functions and the like. The ICAM (at) Exo (at) MPNs can remarkably relieve kidney crystal deposition, oxidative stress and inflammatory response induced by calcium oxalate, and the protective effect of the ICAM (at) Exo (at) MPNs is related to regulation and control of an SLC1A7 / MerTK signal channel. The invention provides an efficient and safe new strategy for preventing and treating the calcium oxalate kidney injury.

The invention relates to the technical field of medicines, in particular to application of ginsenoside in preparation of medicines for improving kidney inflammation and enhancing uric acid excretion. It is found for the first time that ginsenoside Rg2 can reduce systematic and kidney inflammatory reactions by reducing expression levels of inflammatory factors LPS, TNF-alpha and IL-1beta; by down-regulating the expression level of fibrosis marker molecules alpha-SMA and Smad3, the effect of improving HUA-related kidney inflammation and fibrosis is achieved; by up-regulating the expression levels of uric acid transporters OAT1, OAT3 and ABCG2, the active transport and excretion ability of the kidney to uric acid is enhanced. The discovery can generate great influence on research and treatment of relieving hyperuricemia, and has clinical practical value.

The invention discloses application of lactobacillus delbrueckii JNL0010 in preparation of uric acid lowering drugs, and belongs to the technical field of microorganisms. The lactobacillus delbrueckii JNL0010 is preserved in the China General Microbiological Culture Collection Center on June 24, 2024, the preservation address is No. 3, No.1 yard, Beichen West Road, Chaoyang District, Beijing, and the preservation number is CGMCC No. 31042. Animal experiment results show that the lactobacillus delbrueckii JNL0010 can significantly reduce the blood uric acid level of a hyperuricemia model mouse and relieve the kidney inflammation level, and shows huge application value. The lactobacillus delbrueckii JNL0010 not only can degrade purine and nucleoside and reduce serum uric acid, but also has a certain protection effect on kidneys, and compared with drugs, the lactobacillus delbrueckii JNL0010 is higher in safety, small in side effect and wide in market prospect.

The invention discloses an application of 2-deoxy-D-glucose in preparation of a medicine for resisting systemic lupus erythematosus, and the 2-deoxy-D-glucose acts on an SLE (systemic lupus erythematosus) model mouse. According to the application, anti-double-stranded DNA antibodies, antinuclear antibodies and IgG in serum of SLE model mice can be reduced, kidney inflammation of the SLE model mice can be inhibited, kidney collagen deposition of the SLE model mice can be relieved, kidney glycogen accumulation of the SLE model mice can be reduced, kidney C3 complement can be reduced, and the application can be applied to preparation of anti-systemic lupus erythematosus drugs. The treatment process is simple, free of toxic and side effects, safe and reliable.

This invention discloses a butyrate prodrug co-assembled with artesunate, its preparation method, and its application in kidney diseases, belonging to the field of biomedical technology. The invention first uses docosahexaenoic acid (DHA) as a hydrophobic framework, coupling it with 2,2'-dithiodiethanol to introduce disulfide bonds, and then grafts butyrate via esterification to obtain a butyrate prodrug. The butyrate prodrug and artesunate self-assemble through non-covalent interactions to obtain a co-assembled drug in nanoparticle form. This nanomedicine possesses excellent long-term in vivo circulation and passive targeted accumulation in the kidneys, and can achieve targeted drug release in response to the high-glutathione microenvironment within lesion cells. The two active ingredients synergistically exert metabolic regulation, anti-inflammatory, and antioxidant effects, inhibiting kidney inflammation and oxidative stress at multiple targets, protecting renal tubular epithelial cells, and effectively intervening in the pathological process of acute kidney injury. Furthermore, this drug has high biosafety, is simple to prepare, and is easy to scale up, showing broad application prospects in the prevention and treatment of kidney diseases.

The invention discloses a method for treating lupus nephritis by using exosomes and related products thereof, new application of iPSC exosomes and iMac exosomes as drugs for treating lupus nephritis is discovered and confirmed for the first time, and the iPSC exosomes and iMac exosomes can significantly inhibit renal fibrosis, renal inflammatory response and renal pathological glycogen deposition, and can be used for treating lupus nephritis. The compound has an excellent treatment effect on the lupus nephritis, can be used for preparing the medicine for treating the lupus nephritis, provides a new direction for research and development of the medicine for treating the lupus nephritis, and has a wide application prospect in the field of treatment of the lupus nephritis.

Provided is use of a complement factor B inhibitor in the preparation of a drug for treating or preventing IgA nephropathy or a disease or condition related thereto. Specifically, provided is use of a compound represented by formula I or a pharmaceutically acceptable salt thereof or a hydrate thereof in the preparation of a drug for treating or preventing IgA nephropathy or a disease or condition related thereto. The drug can effectively reduce creatinine and urea nitrogen levels in patients with IgA nephropathy, reduce renal inflammation and / or fibrosis in patients with IgA nephropathy, and provide a novel, effective and safe option for the treatment of IgA nephropathy.

The invention discloses an application of cordyceps guangdongensis sporocarp polysaccharide in preparation of a product for treating and improving diabetic nephropathy. Experimental results show that the cordyceps guangdongensis sporocarp polysaccharide can treat and improve the diabetic nephropathy, improve the renal function, reduce the levels of serum urea nitrogen and serum creatinine, and reduce the level of uremia toxin indolesulfuric acid phenol in the plasma of diabetic mice; kidney inflammation is improved, and mRNA expression of IL-6, TNF-alpha, IL-1beta and MCP-1 in the kidney is reduced; the oxidative stress and fibrosis of the kidney are inhibited, and the mRNA expression of Rac1, keap1, Ncf2 and Nsf11c of the kidney is reduced; the abundance of pathogenic bacteria in intestinal tracts and kidneys is reduced, and the pathogenic bacteria are mainly Escherichia.

The invention features methods for the treatment of Alport syndrome using a polypeptide containing an extracellular ActRII variant, such as a polypeptide containing an extracellular ActRII chimera or an extracellular ActRIIB variant. The polypeptide may include an extracellular ActRII chimera or an extracellular ActRIIB variant fused to an Fc domain monomer. Treatment of Alport syndrome with a polypeptide described herein may reduce kidney inflammation, reduce kidney fibrosis, slow disease progression, and / or improve kidney function, which may reduce or delay the need for a kidney transplant or dialysis.

The present invention relates to a bacterial agent for alleviating hyperuricemia and its application. The bacterial strain in the bacterial agent for alleviating hyperuricemia is Akkermansia muciniphila. Akkermansia muciniphila Akk09 strain and Bifidobacterium animalis subsp. lactis Bifidobacterium animalum subsp. milk The two strains are composed of the BLa80 strain. They complement and enhance each other, synergizing their effects in alleviating hyperuricemia, specifically by lowering blood uric acid levels; inhibiting xanthine oxidase activity; reducing urea nitrogen and creatinine levels; alleviating kidney inflammation and oxidative stress caused by hyperuricemia; and regulating intestinal flora disturbances caused by hyperuricemia.

The invention provides application of a composition beneficial to pet kidney health, the composition comprises a yeast extract I, Omega-3 fatty acid, a turmeric extract, a yeast extract II, a green tea extract, a gynostemma pentaphylla extract and glutamine, and the composition is applied to protection of pet kidney health. The yeast extract I contains SAM-e, the turmeric extract contains curcumin, and the yeast extract II contains glutathione. The traditional Chinese medicine composition disclosed by the invention shows a curative effect obviously superior to that of a traditional product such as Shenan capsules in the aspects of reducing renal function indexes, improving pathological changes of kidney tissues, inhibiting expression of related genes of kidney inflammation and the like. Experimental results show that the optimal effects are achieved in five dimensions of oxidative stress, inflammatory response, fat metabolism, safety and mechanism verification, and the effectiveness and safety of the composition are fully proved.

The invention relates to a bacterial agent for relieving hyperuricemia and an application of the bacterial agent. The bacterial strain in the bacterial agent for relieving the hyperuricemia is composed of an Ackermania muciniphila Akk09 bacterial strain and a Bifidobacterium animalis subsp. Lactis BLa80 bacterial strain, and the bacterial strain in the bacterial agent for relieving the hyperuricemia is composed of an Akkermania muciniphila Akk09 bacterial strain and a Bifidobacterium animalis subsp. Lactis BLa80 bacterial strain. The two strains can cooperate with each other and promote each other, and have a synergistic effect on the aspect of relieving hyperuricemia, specifically, the level of blood uric acid is reduced; the activity of xanthine oxidase is inhibited; the urea nitrogen and creatinine levels are reduced; kidney inflammation and oxidative stress caused by hyperuricemia are relieved; the intestinal flora disorder caused by high uric acid is regulated.

The invention belongs to the technical field of medicines, and particularly relates to application of a traditional Chinese medicine compound composition in preparation of medicines for resisting acute and chronic renal injury and renal fibrosis. The traditional Chinese medicine compound composition has remarkable effects of resisting acute kidney injury and chronic kidney injury and improving the degree of renal fibrosis caused by the kidney injury, and can be used for improving and treating acute and chronic kidney injury and renal fibrosis diseases caused by the kidney injury. According to the traditional Chinese medicine compound composition, the acute and chronic renal injury is treated by reducing the oxidative stress level, regulating an inflammation signal channel and inhibiting kidney inflammation so as to regulate and control the immune microenvironment of the kidney, and the renal fibrosis caused by the renal injury is improved. The invention provides a new medicine with obvious curative effect and small adverse reaction for patients with acute and chronic renal injury and renal fibrosis caused by renal injury, so as to relieve the pain of the patients.

The invention provides an application of dihydroberberine in preparation of a medicine for treating diabetic nephropathy. The application finds that dihydroberberine can obviously relieve kidney inflammation and fibrosis lesion in diabetic nephropathy and has an obvious protection effect on renal tubular epithelial cell injury induced by high glucose and high fat, and the bioavailability is obviously improved compared with berberine.

The present invention pertains to a pharmaceutical composition for the prevention or treatment of kidney disease, a kidney inflammation inhibitor, an inflammatory cell death inhibitor for the kidneys, or a food for the prevention or improvement of kidney disease, that include D-alanine or a derivative thereof. In addition, the present invention pertains to the use of D-alanine or a derivative thereof, for the production of a pharmaceutical composition for the prevention or treatment of kidney disease.

The invention provides application of pigeon pea extract and active ingredients in preparation of drugs or functional food for relieving hyperuricemia. Animal experiment research finds that intervention of pigeon pea extract and pinostrobin significantly reduces serum uric acid content of a hyperuricemia mouse, prevents serum creatinine and / or serum urea nitrogen in vivo from increasing, and can increase urine urea nitrogen and / or urine creatinine excretion; meanwhile, the pigeonpea extract and the pinostrobin can restore the kidney and liver coefficients of a hyperuricemia mouse to a normal level, remarkably relieve kidney injury caused by hyperuricemia, inhibit kidney inflammation / fibrosis reaction and restore the physiological state of the kidney to the level of a normal mouse.

The present invention relates to the technical field of anti-aging drugs, and in particular to the application of chaetocin in anti-aging. The present invention uses an aging cell model and an aging mouse model to screen and obtain a drug chaetocin (chaetocin) with anti-aging effects. After cell and mouse experiments, it was verified that chaetocin can not only effectively inhibit hair loss, weight loss, cardiac fibrosis, liver fibrosis, kidney fibrosis, spleen fibrosis, lung fibrosis, arterial adventitial fibrosis and smooth muscle loss, but also prolong life, increase abdominal fat, and relieve cardiac inflammation, kidney inflammation, liver inflammation, lung inflammation, spleen inflammation, small intestine inflammation and skin inflammation. The chaetocin provided by the present invention can be used as an anti-aging drug and applied to the research and development of drugs for treating a variety of aging-related diseases.

The present disclosure belongs to the technical field of biological medicine, and particularly relates to the application of finerenone in the preparation of a drug for treating hypertensive renal injury. The present disclosure provides the application of finerenone in the preparation of a drug for preventing and / or treating hypertensive renal injury, specifically, by using a deoxycorticosterone acetate-salt-induced hypertensive mouse model and a primary mouse renal tubular epithelial cell-bone marrow-derived macrophage co-culture model, it is first revealed that aldosterone and salt corticosteroid receptor signals mediate cell-to-cell communication by promoting PANX1-dependent ATP release in renal tubular epithelial cells, and then activate macrophage P2X7, activate NLRP3-mediated macrophage pyroptosis, and aggravate the molecular mechanism of aldosterone-driven renal inflammation and fibrosis. The present disclosure also provides the application of a substance targeting a PANX1 / extracellular ATP / P2X7 signal axis in the preparation of a drug for preventing and / or treating hypertensive renal injury.

The application belongs to the technical field of plant lactobacillus, and particularly relates to a plant lactobacillus LPU3 and application of the plant lactobacillus LPU3 in relieving hyperuricemia. The plant lactobacillus LPU3 has the functions of degrading uric acid in vitro, inhibiting xanthine oxidase in vitro, intervening hyperuricemia, inhibiting metabolic enzymes, improving kidney injury caused by hyperuricemia, improving kidney inflammation and oxidative stress caused by hyperuricemia, and improving intestinal flora disorder caused by hyperuricemia.

The invention discloses a compound and application thereof in preparation of a medicine for treating systemic lupus erythematosus. A series of novel small molecule compounds are designed based on DHA by utilizing a PROTAC technology, the novel small molecule compounds have ligands combined with E3 ubiquitin ligase protein and ligands for targeted degradation of protein, the compound shown in the formula (II-1) degrades CARD6 protein through an ubiquitin enzyme system, phenotypic polarization of THP-1 macrophages induced by LPS + IFN-gamma to M1 can be inhibited, CARD6 can be degraded, and the compound can be used for preparing a medicine for preventing and controlling the expression of the compound in the formula (II-1). The inflammation is improved; the compound can effectively improve the renal function of an MRL / lpr model mouse and relieve the renal inflammatory response of the MRL / lpr mouse, can be further developed into a medicine for treating SLE, and has a wide application prospect.

The present invention provides a composition having the effects of lowering uric acid and improving renal function, and its preparation method, application and product, which belong to the field of application of traditional Chinese medicine. The composition is composed of the following components: raw astragalus, smilax glabra, mistletoe, salvia miltiorrhiza and orientalis. The composition provided by the present invention is used in combination with raw astragalus, smilax glabra, mistletoe, salvia miltiorrhiza and orientalis, and the obtained composition can be used to treat hyperuricemia or its related diseases, with significant efficacy and small toxic and side effects. The composition is used for the late treatment of hyperuricemia, treatment of joint pain, and poor flexion and extension. At the same time, the composition has a certain kidney protection effect, which can reduce renal inflammation and fibrosis.